Baxter International Inc. has agreed to sell its renal care business, including Vantive Health LLC and related entities, to Carlyle-managed affiliates for $3.8 billion, expecting to receive about $3.5 billion in cash after adjustments, with the deal anticipated to close in late 2024 or early 2025.